Literature DB >> 24166198

Cotransplantation of human umbilical cord-derived mesenchymal stem cells and umbilical cord blood-derived CD34⁺ cells in a rabbit model of myocardial infarction.

Tong Li1, Qunxing Ma, Meng Ning, Yue Zhao, Yuelong Hou.   

Abstract

The objective of the study is to investigate the effect of hypoxic preconditioning on the immunomodulatory properties of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and the effect of cotransplantation of hUC-MSCs and human umbilical cord blood (hUCB)-derived CD34(+) cells in a rabbit model of myocardial infarction. hUC-MSCs with or without hypoxic preconditioning by cobalt chloride were plated in a 24-well plate, and then cocultured with hUCB-CD34(+) cells and PBMCs for 96 h at 37 °C in a 5% CO₂ incubator. For the negative control, hUC-MSCs were omitted. The groups were divided as follows: A1 = HP-MSCs + hUCB-CD34(+) cells + PBMC, A2 = hUC-MSCs + hUCB-CD34(+) cells + PBMC, Negative Control = hUCB-CD34(+) cells + PBMC. Culture supernatants of each group were collected, and the IL-10 and IFN-γ levels were measured by ELISA. A rabbit model of MI was established using a modified Fujita method. The animals were then randomized into three groups and received intramyocardial injections of 0.4 ml of PBS alone (n = 8, PBS group), hUC-MSCs in PBS (n = 8, hUC-MSCs group), or hUC-MSCs + CD34(+) cells in PBS (n = 8, Cotrans group), at four points in the infarct border zone. Echocardiography was performed at baseline, 4 weeks after MI induction, and 4 weeks after cell transplantation, respectively. Stem cell differentiation and neovascularization in the infracted area were characterized for the presence of cardiac Troponin I (cTnI) and CD31 by immunohistochemical staining, and the extent of myocardial fibrosis was evaluated by hematoxylin and eosin (H&E) and Masson's trichrome. IFN-γ was 27.00 ± 1.11, 14.20 ± 0.81, and 7.22 ± 0.14 pg/ml, and IL-10 was 31.68 ± 3.08, 61.42 ± 1.08, and 85.85 ± 1.80 pg/ml for the Control, A1 and A2 groups, respectively, which indicated that hUCB-CD34(+) cells induced immune reaction of peripheral blood mononuclear cells, whereas both hUC-MSCs and HP-MSCs showed an immunosuppressive effect, which, however, was attenuated by hypoxic preconditioning. The Cotrans group had less collagen deposition in the infarcted myocardium and better heart function than the hUC-MSCs or PBS group. The presence of cTnI-positive cells and CD31-positive tubular structures indicated the differentiation of stem cells into cardiomyocytes and neovascularization. The microvessel density was 12.19 ± 3.05/HP for the hUC-MSCs group and 31.63 ± 2.45/HP for the Cotrans group, respectively (P < 0.01). As a conclusion, both hUC-MSCs and HP-MSCs have an immunosuppressive effect on lymphocytes, which, however, can be attenuated by hypoxic preconditioning. Cotransplantation of hUC-MSCs and hUCB-CD34(+) cells can improve heart function and decrease collagen deposition in post-MI rabbits. Thus, a combined regimen of hUC-MSCs and hUCB-CD34(+) cells would be more desirable than either cells administered alone. This is most likely due to the increase of cardiomyocytes and enhanced angiogenesis in the infarcted myocardium.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24166198     DOI: 10.1007/s11010-013-1874-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

1.  [Mesenchymal stem cells for bone tissue engineering].

Authors:  R K Schneider; S Neuss; R Knüchel; A Perez-Bouza
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes.

Authors:  Changhui Zhou; Bo Yang; Yi Tian; Hongliang Jiao; Wendi Zheng; Jian Wang; Fangxia Guan
Journal:  Cell Immunol       Date:  2011-09-29       Impact factor: 4.868

3.  Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials.

Authors:  Lu-Lu Lu; Yong-Jun Liu; Shao-Guang Yang; Qin-Jun Zhao; Xin Wang; Wei Gong; Zhi-Bo Han; Zhen-Shu Xu; Yong-Xin Lu; Delong Liu; Zhi-Zhe Chen; Zhong-Chao Han
Journal:  Haematologica       Date:  2006-07-25       Impact factor: 9.941

4.  Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment.

Authors:  Yoshitaka Iso; Jeffrey L Spees; Claudia Serrano; Benjamin Bakondi; Radhika Pochampally; Yao-Hua Song; Burton E Sobel; Patrick Delafontaine; Darwin J Prockop
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

5.  Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization.

Authors:  Takatoshi Sato; Yoshitaka Iso; Taro Uyama; Keisuke Kawachi; Kohei Wakabayashi; Yasutoshi Omori; Teruko Soda; Makoto Shoji; Shinji Koba; Shin-Ichiro Yokoyama; Noboru Fukuda; Satoshi Saito; Takashi Katagiri; Youichi Kobayashi; Youichi Takeyama; Akihiro Umezawa; Hiroshi Suzuki
Journal:  Lab Invest       Date:  2011-01-31       Impact factor: 5.662

6.  Transplantation of bone marrow-derived stem cells improves myocardial diastolic function: strain rate imaging in a model of hibernating myocardium.

Authors:  Carsten Schneider; Kai Jaquet; Stephan Geidel; Thomas Rau; Rainer Malisius; Sigrid Boczor; Tomacz Zienkiewicz; Karl-Heinz Kuck; Korff Krause
Journal:  J Am Soc Echocardiogr       Date:  2009-07-31       Impact factor: 5.251

7.  Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action.

Authors:  Jingxiong Wang; Sui Zhang; Brian Rabinovich; Luc Bidaut; Suren Soghomonyan; Mian M Alauddin; James A Bankson; Elizabeth Shpall; James T Willerson; Juri G Gelovani; Edward T H Yeh
Journal:  Circ Res       Date:  2010-05-06       Impact factor: 17.367

8.  Expanded human cord blood-derived endothelial progenitor cells salvage infarcted myocardium in rats with acute myocardial infarction.

Authors:  Cheng-Heng Hu; Zhi-Ming Li; Zhi-Min Du; Ai-Xia Zhang; Jamal S Rana; Dong-Hong Liu; Da-Ya Yang; Gui-Fu Wu
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-05       Impact factor: 2.557

9.  Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction.

Authors:  Adam R Williams; Konstantinos E Hatzistergos; Benjamin Addicott; Fred McCall; Decio Carvalho; Viky Suncion; Azorides R Morales; Jose Da Silva; Mark A Sussman; Alan W Heldman; Joshua M Hare
Journal:  Circulation       Date:  2012-12-05       Impact factor: 29.690

10.  IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells.

Authors:  Karen English; Frank P Barry; Ciara P Field-Corbett; Bernard P Mahon
Journal:  Immunol Lett       Date:  2007-04-26       Impact factor: 3.685

View more
  10 in total

Review 1.  The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity.

Authors:  Huanrong Lan; Qi Xue; Yuyao Liu; Ketao Jin; Xingliang Fang; Hong Shao
Journal:  Cell Tissue Res       Date:  2021-01-12       Impact factor: 5.249

2.  Human umbilical cord mesenchymal stem cells-derived exosomes transfers microRNA-19a to protect cardiomyocytes from acute myocardial infarction by targeting SOX6.

Authors:  Lin Huang; Lu Yang; Yin Ding; Xinghua Jiang; Zhen Xia; Zhigang You
Journal:  Cell Cycle       Date:  2020-01-10       Impact factor: 4.534

Review 3.  Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor.

Authors:  I Dela Peña; P R Sanberg; S Acosta; N Tajiri; S Z Lin; C V Borlongan
Journal:  J Neurosurg Sci       Date:  2014-05-20       Impact factor: 2.279

4.  Drug-like delivery methods of stem cells as biologics for stroke.

Authors:  Julian P Tuazon; Vanessa Castelli; Cesar V Borlongan
Journal:  Expert Opin Drug Deliv       Date:  2019-08-05       Impact factor: 6.648

5.  Mesenchymal Stem Cells and Mononuclear Cells From Cord Blood: Cotransplantation Provides a Better Effect in Treating Myocardial Infarction.

Authors:  Gecai Chen; Aihuan Yue; Hong Yu; Zhongbao Ruan; Yigang Yin; Ruzhu Wang; Yin Ren; Li Zhu
Journal:  Stem Cells Transl Med       Date:  2016-01-21       Impact factor: 6.940

Review 6.  Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).

Authors:  Aastha Singh; Abhishek Singh; Dwaipayan Sen
Journal:  Stem Cell Res Ther       Date:  2016-06-04       Impact factor: 6.832

7.  Intravenous injection of allogeneic umbilical cord-derived multipotent mesenchymal stromal cells reduces the infarct area and ameliorates cardiac function in a porcine model of acute myocardial infarction.

Authors:  Meikuang Lim; Weiqiang Wang; Lu Liang; Zhi-Bo Han; Zongjin Li; Jie Geng; Meng Zhao; Honghong Jia; Jie Feng; Zhe Wei; Baoquan Song; Jiemin Zhang; Jun Li; Tianwen Liu; Fan Wang; Ting Li; Jianming Li; Yihu Fang; Jianhua Gao; Zhongchao Han
Journal:  Stem Cell Res Ther       Date:  2018-05-11       Impact factor: 6.832

Review 8.  Cell therapy for central nervous system disorders: Current obstacles to progress.

Authors:  Takao Yasuhara; Satoshi Kawauchi; Kyohei Kin; Jun Morimoto; Masahiro Kameda; Tatsuya Sasaki; Brooke Bonsack; Chase Kingsbury; Naoki Tajiri; Cesario V Borlongan; Isao Date
Journal:  CNS Neurosci Ther       Date:  2019-10-17       Impact factor: 5.243

Review 9.  Granulocyte-colony stimulating factor and umbilical cord blood cell transplantation: Synergistic therapies for the treatment of traumatic brain injury.

Authors:  Michael G Liska; Ike Dela Peña
Journal:  Brain Circ       Date:  2017-10-12

10.  Evidence for the existence of CD34+ angiogenic stem cells in human first-trimester decidua and their therapeutic for ischaemic heart disease.

Authors:  Long Bai; Lu Sun; Wei Chen; Kai-Yu Liu; Chun-Feng Zhang; Fei Wang; Gui-Huan Zhang; Ye Huang; Jing-Xuan Li; Ying Gao; Xin Sun; Wei Liu; Guo-Qing Du; Ren-Ke Li; Ming-Li Huang; Hai Tian
Journal:  J Cell Mol Med       Date:  2020-09-08       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.